Systemic immunomodulatory agents are indicated for atopic dermatitis (AD) when:
- Topical and/or phototherapy do not adequately control the signs and symptoms of AD.
- AD inflicts a significant negative physical, emotional, or social impact.
This treatment should be adjusted to the “minimal effective dose once response is attained and sustained.” There is currently not enough evidence to recommend optimal dosing, duration of therapy, or precise monitoring protocols.